

Preliminary Amendment
Serial No. 09/003,869
Page 2 of 6

18. (Twice Amended) The method according to any one of claims 1-15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

19. (Twice Amended) The method according to any one of claims 1-15, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

20. (Twice Amended) The method according to any one of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula I.

21. (Twice Amended) The method according to any one of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula II.

22. (Twice Amended) The method according to any one of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula III.

32. (Once Amended) The method according to any one of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula II, and wherein said method further comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

33. (Once Amended) The method according to any one of claims 1-15 wherein said exendin agonist is an exendin agonist according to Formula III, and wherein said method further comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.